title: The cost utility of solifenacin in the treatment of overactive bladder.
abstract: OBJECTIVE
  Overactive bladder may cause significant discomfort to patients. The standard therapy for overactive bladder includes behavioural therapy and sometimes medication. Recently, a new medication (solifenacin 5 and 10 mg) was developed for treatment of overactive bladder. The objective of this study was to assess the cost utility of solifenacin 5 and 10 mg for overactive bladder.
  
  
  METHODS
  We developed a Markov model to estimate the cost per quality adjusted life years (QALY) over a period of 12-months. Model parameters were based on randomized clinical trials for solifenacin 5 and 10 mg. Data on utility scores were taken from the literature.
  
  
  RESULTS
  The incremental cost per QALY for solifenacin 5 mg and solifenacin 10 mg compared with placebo were 17,602 pounds and 24,464 pounds respectively. Sensitivity analyses showed that these results were robust to changes of relevant input data.
  
  
  CONCLUSIONS
  Solifenacin 5 and 10 mg are cost-effective treatments in patients with overactive bladder.
authors.affiliation: Institute for Medical Technology Assessment, Erasmus MC, PO Box 1738, Rotterdam 3000 DR, The Netherlands. l.hakkaart-vanroijen@erasmusmc.nl
authors.forename: Leona
authors.initials: L
authors.lastname: Hakkaart
authors.forename: Paul
authors.initials: P
authors.lastname: Verboom
authors.forename: Richard
authors.initials: R
authors.lastname: Phillips
authors.forename: Maiwenn J
authors.initials: MJ
authors.lastname: Al
mesh_terms: D000328:Adult; D003362:Cost-Benefit Analysis; D041382:Diapers, Adult; D016527:Drug Costs; D005260:Female; D006801:Humans; D008297:Male; D008390:Markov Chains; D018727:Muscarinic Antagonists / Q000191:economics* / Q000627:therapeutic use; D010349:Patient Compliance; D019057:Quality-Adjusted Life Years; D011812:Quinuclidines / Q000191:economics* / Q000627:therapeutic use; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000191:economics* / Q000627:therapeutic use; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000191:economics
chemical_list: D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate